Analysis of Time-To-Onset of Interstitial Lung Disease After the Administration of Small Molecule Molecularly-Targeted Drugs

Yakugaku Zasshi - Japan
doi 10.1248/yakushi.17-00194
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pharmaceutical Society of Japan

Related search

Analysis of Time-To-Onset and Onset-Pattern of Interstitial Lung Disease After the Administration of Monoclonal Antibody Agents

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2018English

Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2017English

Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients With Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy

Journal of Cancer
Oncology
2018English

Binding of Small Molecule Drugs to Porcine Vitreous Humor

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2018English

Delivery of Molecularly Targeted Therapy to Malignant Glioma, a Disease of the Whole Brain

Expert Reviews in Molecular Medicine
Molecular MedicineMolecular Biology
2011English

Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs

Frontiers in Oncology
Cancer ResearchOncology
2019English

Interstitial Lung Disease

European Respiratory Review
PulmonaryRespiratory Medicine
2014English

Adhesion Molecule Expression in the Lung: A Comparison Between Normal and Diffuse Interstitial Lung Disease

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
1998English

Screening of Gene Mutations in Lung Cancer for Qualification to Molecularly Targeted Therapies

2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy